Pliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Sells $112,427.70 in Stock

Pliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Mike Ouimette sold 10,230 shares of the stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $10.99, for a total transaction of $112,427.70. Following the completion of the transaction, the general counsel now owns 70,544 shares in the company, valued at $775,278.56. This represents a 12.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Mike Ouimette also recently made the following trade(s):

• On Friday, January 17th, Mike Ouimette sold 13,270 shares of Pliant Therapeutics stock. The stock was sold at an average price of $11.20, for a total transaction of $148,624.00.

Pliant Therapeutics Trading Down 1.4 %

Shares of PLRX traded down $0.15 during trading hours on Wednesday, reaching $10.92. The stock had a trading volume of 700,759 shares, compared to its average volume of 454,935. The company has a market cap of $664.48 million, a P/E ratio of -3.27 and a beta of 1.05. Pliant Therapeutics, Inc. has a 52 week low of $10.22 and a 52 week high of $18.92. The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09. The firm has a 50-day moving average of $13.24 and a 200 day moving average of $13.08.

Pliant Therapeutics (NASDAQ:PLRX) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.99) by $0.04. On average, sell-side analysts expect that Pliant Therapeutics, Inc. will post -3.65 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $38.00 price target on shares of Pliant Therapeutics in a research report on Friday, November 8th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $40.50.

Institutional Trading of Pliant Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Great Point Partners LLC boosted its holdings in shares of Pliant Therapeutics by 42.4% in the second quarter. Great Point Partners LLC now owns 2,636,864 shares of the company’s stock valued at $28,346,000 after buying an additional 785,000 shares during the period. Renaissance Technologies LLC lifted its position in Pliant Therapeutics by 233.8% in the 2nd quarter. Renaissance Technologies LLC now owns 253,369 shares of the company’s stock valued at $2,724,000 after acquiring an additional 177,469 shares in the last quarter. Checkpoint Capital L.P. boosted its stake in Pliant Therapeutics by 63.7% in the 3rd quarter. Checkpoint Capital L.P. now owns 380,000 shares of the company’s stock worth $4,260,000 after purchasing an additional 147,800 shares during the period. Polar Asset Management Partners Inc. increased its holdings in Pliant Therapeutics by 265.2% during the 3rd quarter. Polar Asset Management Partners Inc. now owns 170,200 shares of the company’s stock worth $1,908,000 after purchasing an additional 123,600 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of Pliant Therapeutics in the 2nd quarter valued at about $865,000. 97.30% of the stock is currently owned by institutional investors and hedge funds.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.